Compare Intel Corp (INTC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs GeneDx Holdings Corp — how do they compare? Intel Corp trades at $102.1 (market cap $492.85B), while GeneDx Holdings Corp trades at $82.16 (market cap $2.44B). The key difference: Intel Corp is far larger — about 202× GeneDx Holdings Corp's market cap, and Intel Corp pays a 2.24% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| INTC | WGS | |
|---|---|---|
Market Cap | $492.85B | $2.44B |
Volume | 43,552,012 | — |
Sector | Technology | Technology |
52-Week High | $140.94 | $167.51 |
52-Week Low | $21.81 | $34.51 |
Enterprise Value | $513.66B | $2.48B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $100.51, up 3.07% today, with a bullish technical signal and recent earnings beats. Revenue grew 25% year-over-year in Q2 2026, driven by data center and AI segments, though net income margins remain negative. The company recently upsized a stock offering to $20 billion to fund AI and manufacturing investments, causing some investor concern over dilution but supporting long-term growth initiatives.
Outlook is mixed: strong revenue growth and analyst consensus price target of $116.67 suggest upside, but high valuation ratios, negative profitability, and execution risks in the capital-intensive foundry business pose challenges. Investor sentiment is cautiously optimistic amid the AI-driven turnaround narrative.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
